Commodore Capital
Latest statistics and disclosures from Commodore Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are RLAY, ALKS, ELVN, COGT, SYRE, and represent 37.82% of Commodore Capital's stock portfolio.
- Added to shares of these 10 stocks: ERAS (+$51M), DMRA (+$50M), DFTX (+$38M), EYPT (+$36M), CRVS (+$33M), NUVL (+$29M), COGT (+$27M), CATX (+$26M), ALKS (+$23M), OCUL (+$22M).
- Started 13 new stock positions in DMRA, ZURA, RLMD, KPTI, ERAS, OCUL, ANTX, DFTX, IPSC, EYPT. Helix Acquisition Corp Iii, CRVS, CATX.
- Reduced shares in these 10 stocks: TERN (-$60M), XENE (-$57M), ELVN (-$56M), ORKA (-$53M), PTGX (-$39M), TYRA (-$35M), CTMX (-$33M), MNMD (-$27M), CNTA (-$25M), SYRE (-$24M).
- Sold out of its positions in DRUG, CNTA, CTNM, CTMX, MNMD, ORKA, PTGX, RAPT, REPL, TERN.
- Commodore Capital was a net seller of stock by $-36M.
- Commodore Capital has $1.7B in assets under management (AUM), dropping by 15.06%.
- Central Index Key (CIK): 0001831942
Tip: Access up to 7 years of quarterly data
Positions held by Commodore Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Commodore Capital
Commodore Capital holds 36 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Relay Therapeutics (RLAY) | 9.8 | $169M | 17M | 9.95 |
|
|
| Alkermes SHS (ALKS) | 8.6 | $149M | +18% | 4.2M | 35.36 |
|
| Enliven Therapeutics (ELVN) | 7.4 | $128M | -30% | 3.3M | 39.20 |
|
| Cogent Biosciences (COGT) | 6.4 | $111M | +31% | 2.9M | 38.49 |
|
| Spyre Therapeutics Com New (SYRE) | 5.6 | $97M | -19% | 1.9M | 50.44 |
|
| Tyra Biosciences (TYRA) | 5.5 | $95M | -26% | 2.5M | 38.30 |
|
| Celldex Therapeutics Com New (CLDX) | 4.9 | $86M | +5% | 2.7M | 31.72 |
|
| Nuvalent Inc-a (NUVL) | 4.9 | $85M | +51% | 834k | 102.45 |
|
| Amylyx Pharmaceuticals (AMLX) | 4.5 | $79M | 5.7M | 13.90 |
|
|
| Kymera Therapeutics (KYMR) | 3.6 | $63M | 750k | 83.29 |
|
|
| Alto Neuroscience Com Shs (ANRO) | 3.5 | $61M | +49% | 2.7M | 22.48 |
|
| Pharvaris N V (PHVS) | 3.1 | $54M | 1.9M | 28.25 |
|
|
| Erasca (ERAS) | 3.0 | $51M | NEW | 3.2M | 16.18 |
|
| Damora Therapeutics Com New (DMRA) | 2.9 | $50M | NEW | 1.9M | 25.90 |
|
| Xenon Pharmaceuticals (XENE) | 2.8 | $48M | -54% | 825k | 58.15 |
|
| Definium Therapeutics Com Shs (DFTX) | 2.2 | $38M | NEW | 2.0M | 18.90 |
|
| Lb Pharmaceuticals Com Shs (LBRX) | 2.1 | $37M | 1.5M | 24.66 |
|
|
| Eyepoint Com New (EYPT) | 2.1 | $36M | NEW | 2.8M | 12.89 |
|
| Nurix Therapeutics (NRIX) | 2.0 | $35M | 2.3M | 15.50 |
|
|
| Corvus Pharmaceuticals (CRVS) | 1.9 | $33M | NEW | 2.3M | 14.63 |
|
| Assembly Biosciences Com New (ASMB) | 1.6 | $28M | 1.0M | 27.75 |
|
|
| Perspective Therapeutics Com New (CATX) | 1.5 | $26M | NEW | 6.3M | 4.17 |
|
| Soleno Therapeutics (SLNO) | 1.3 | $22M | -45% | 652k | 33.48 |
|
| Ocular Therapeutix (OCUL) | 1.3 | $22M | NEW | 2.6M | 8.47 |
|
| Century Therapeutics (IPSC) | 1.1 | $20M | NEW | 8.7M | 2.26 |
|
| Zura Bio Class A Ord Shs (ZURA) | 1.1 | $19M | NEW | 3.3M | 5.95 |
|
| Sab Biotherapeutics Com New (SABS) | 1.0 | $17M | 4.4M | 3.83 |
|
|
| Palisade Bio (PALI) | 0.7 | $13M | -37% | 7.2M | 1.75 |
|
| Karyopharm Therapeutics Com New (KPTI) | 0.6 | $11M | NEW | 2.0M | 5.57 |
|
| Inhibikase Therapeutics Com New (IKT) | 0.5 | $9.1M | 5.4M | 1.68 |
|
|
| An2 Therapeutics (ANTX) | 0.5 | $8.0M | NEW | 2.3M | 3.42 |
|
| Pepgen (PEPG) | 0.5 | $7.9M | +31% | 4.5M | 1.77 |
|
| Avalo Therapeutics Com New (AVTX) | 0.4 | $7.2M | 483k | 14.93 |
|
|
| Helix Acquisition Corp Iii Usd Cl A Ord Shs | 0.3 | $5.1M | NEW | 500k | 10.16 |
|
| Athira Pharma (LONA) | 0.3 | $4.8M | 464k | 10.28 |
|
|
| Relmada Therapeutics (RLMD) | 0.3 | $4.4M | NEW | 634k | 6.96 |
|
Past Filings by Commodore Capital
SEC 13F filings are viewable for Commodore Capital going back to 2020
- Commodore Capital 2026 Q1 filed May 15, 2026
- Commodore Capital 2025 Q4 filed Feb. 17, 2026
- Commodore Capital 2025 Q3 filed Nov. 14, 2025
- Commodore Capital 2025 Q2 filed Aug. 14, 2025
- Commodore Capital 2025 Q1 filed May 15, 2025
- Commodore Capital 2024 Q4 filed Feb. 14, 2025
- Commodore Capital 2024 Q3 filed Nov. 14, 2024
- Commodore Capital 2024 Q2 filed Aug. 14, 2024
- Commodore Capital 2024 Q1 filed May 15, 2024
- Commodore Capital 2023 Q4 filed Feb. 14, 2024
- Commodore Capital 2023 Q4 restated filed Feb. 14, 2024
- Commodore Capital 2023 Q3 filed Nov. 14, 2023
- Commodore Capital 2023 Q2 filed Aug. 14, 2023
- Commodore Capital 2023 Q1 filed May 15, 2023
- Commodore Capital 2022 Q4 filed Feb. 14, 2023
- Commodore Capital 2022 Q3 filed Nov. 14, 2022